Introduction: Patients presenting with new onset interstitial lung disease (ILD) should be assessed for secondary, potentially treatable, causes. Some patients with rheumatic disease may present with ILD as the first manifestation of their condition. Early diagnosis and treatment of an underlying rheumatic disease can improve patient outcome. As autoimmune screening has evolved to include extended myositis and scleroderma panels, increasing numbers of patients with ILD are being referred forreviewbyarheumatologist.Thiscasehighlightsone suchpatientdiagnosed with new onset ILD during an acute hospital admission but subsequently found to have anunderlying connective tissue disease (CTD). Case description: A 54-year-old previously fit and well man presented to the Emergency Department with a three-month history of progressively worsening shortness of breath and dry cough. He denied any other symptoms, including those in keeping with a connective tissue disease (CTD). His past medical history was unremarkable. His father had a possible diagnosis of Sjö gren's syndrome and his sister had Sjö gren's syndrome with ILD. He had a20 pack year smoking history. On admission his could only walk ten meters before having to stop due to shortness of breath. On auscultation of his chest he had fine inspiratory crepitations in the mid and lower zones. Blood tests revealed an elevated c-reactive protein (CRP) of 96 and erythrocyte sedimentation rate (ESR) of 120. He failed to improve with intravenous antibiotics and his CRP rose to 122. Computer tomography (HRCT) of the chest, abdomen and pelvis revealed bilateral reticulation peripherally in the mid and lower zones and paraseptal/centrilobular emphysematous changes in the upper zones. Pulmonary function tests (PFTs) demonstrated normal spirometry but reduced gas transfer. Anti-cyclic citrullinated peptide (anti-CCP) antibodies, rheumatoid factor, anti-neutrophil cytoplasmic antibodies (ANCA) and HIV screen were negative. Creatine kinase was normal. ANA was positive, with positive anti-Ro-52 antibodies and positive anti-PL12 onan extended myositis panel. A diagnosis of anti-synthetase syndrome was made. He was treated with three 1 gram doses of intravenous methylprednisolone on consecutive days then switched to 40mg of oral prednisolone daily. His inflammatory markers improved and he was discharged home. Monthly cyclophosphamide infusions werecommenced and he has received two doses thus far. Although subjectively the patient does not report much improvement in his breathing as yet, he attends his appointments independently and is able to walk over 50 meters without stopping. Repeat PFTs and HRCT chest are scheduled. Discussion: Patients presenting with ILD with no identifiable cause should be assessed and screened for CTDs. Evaluation should include a thorough history and examination, looking for associated conditions. ILD may be associated with rheumatoid arthritis, systemic sclerosis, polymyositis, dermatomyositis, anti-synthetase syndrome, sarcoidosis, Sjogren's syndrome, mixed connective tissue disease and systemic lupus erythematous (SLE). Pulmonary function tests may demonstrate a restrictive pattern on spirometry, although this can be normal. Gas transfer is often reduced and a carbon monoxide transfer factor of < 40% is indicative of advanced disease. Imaging, usually in the form of high-resolution CT (HRCT), can allow assessment of the pattern of ILD and the potential for reversibility. It can often help avoid the need for lung biopsy. If no clear alternative cause of ILD (eg. drugs, occupational exposure, inhaled substances, infection, radiation) then physicians should consider sending bloods to help excludes CTDs, including creatine kinase, rheumatoid factor, anti-CCP antibodies, anti-nuclear antibodies (with extended myositis and scleroderma panels) and ANCA,even in asymptomatic patients. Case series have demonstrated that ILD may be the only presenting feature in a proportion of those with anti-synthetase syndrome, particularly in patients with anti-PL7 or PL-12. The classic triad of clinical features for anti-synthetase syndrome consists of ILD, myositis and arthritis (mechanic's hands). Our patient had no CTD symptoms at presentation but has gone on to develop Raynaud's and stiffness in his fingers over the last 6 months. He has not at any stage had evidence of myositis, either clinically or serologically, which is in keeping with case series of patients with ILD and PL-12 positivity reporting a proportion as being amyopathic. Particular factors that should prompt screening for anti-synthetase syndrome include female gender, middle age, clinical signs suggestive of aCTD and an NSIP pattern onHRCT. Key learning points: Rheumatic conditions which can present with ILD include rheumatoid arthritis, systemic sclerosis, polymyositis, dermatomyositis, anti-synthetase syndrome, sarcoidosis, Sjö gren's syndrome, mixed connective tissue disease and SLE.Newly presenting ILD patients with no identifiable cause should be checked for rheumatoid factor, anti-CCP antibodies, anti-nuclear antibodies (with extended myositis and scleroderma panel) and ANCA. ILDassociated with anti-synthetase syndrome, polymyositis ordermatomyositis often warrants early treatment with steroid and cyclophosphamide oranother immunosuppressive agent suchas rituximab. Patient characteristics which should prompt screening for anti-synthetase syndrome with extended myositis panel testing include clinical suspicion of CTD, female gender, middle age, CTD symptoms or signs and NSIP pattern onHRCT. All patients presenting with ILD should have pulmonary function tests and imaging to assessseverity of disease. Conflicts of interest: The authors have declared no conflicts of interest. Introduction: We describe the case of a 58-year-old female with a background of primary Sjö gren's syndrome (PSS) and cryptogenic organising pneumonia (COP), who recently presented with worsening of her breathlessness and reduced exercise tolerance. CT pulmonary angiogram (CTPA) ruled out pulmonary embolism (PE) and indicated an improvement in the radiological appearance of her COP. However, an echocardiogram suggested the development of significant pulmonary arterial hypertension (PAH), requiring specialist input for vasodilators, phosphodiesterase inhibitors, endothelin receptor antagonists and diuretics. This case highlights the importance of thoroughly investigating breathlessness in connective tissue disease (CTD) patients and the need to consider dual pathology. Case description: We report a case from 2019 involving a 58-year-old female who was already known to rheumatology with PSS, diagnosed in 2012. She was known to be ANA positive with anti-Ro and anti-La antibodies and had a history of anxiety. She was referred to the respiratory team in 2017, due to 6 months of progressive exertional breathlessness. A CT scan showed features consistent with COP, although lung function was considered to bestable, so notreatment was initiated. Prednisolone was commenced in November 2018, due to worsening breathlessness. Despite this she continued to deteriorate, and in February 2019 her exercise tolerance reduced significantly, with new ankle swelling and postural dizziness. Clinical examination demonstrated a raised JVP. CTPA was negative for pulmonary thromboembolism. An urgent echocardiogram showed a severely dilated right ventricle with impaired systolic function, severe tricuspid regurgitation and an estimated PASP of 81mmgHg, suggestiveof significant PAH. The patient was admitted but developed type 1 respiratory failure and was transferred to a specialist centre for right heart catheterisation, confirming PAH. The patient received intravenous epoprostenol, dopamine and furosemide. The admission was complicated by pyrexia of unknown origin despite prolonged antibiotics, with no microorganisms grown on blood or bronchoscopic cultures. CT chest showed new widespread ground glass changes. Her fevers settled after withdrawal of antimicrobials and she was discharged on oral selexipag, tadalafil, macitentan, furosemide and spironolactone. Her post discharge exercise tolerance is improved, and she has even been able to return to horse riding. Symptoms remain less severe than prior to her hospital admission, although worse than they had been as an inpatient on intravenous therapy; however, her oral medications are still being titrated. Right heart catheterisation, echocardiography and lung function tests will be repeated 4monthspost discharge. Discussion: PSS is not as strongly associated with severe organ involvement compared with other CTDs. At clinic reviews, clinicians tend to focus on dealing with sicca and joint symptoms and lymphoma monitoring. This case emphasises the importanceof screeningforandinvestigating respiratory symptoms, and the importance of considering PAH even when other lung diagnoses arepresent. The case demonstrated several potential causes for breathlessness: worsening COP, PAH and PE. She was diagnosed with COP 6 months after the onset of her sicca symptoms and had been stable until 3 months before presentation. She had regular pulmonary function tests to monitor progress under respiratory follow up. COP is a form of interstitial lung disease (ILD) which is thought to occur when alveolar epithelial injury ultimately results in intra-alveolar fibrosis. Radiological appearances include multiple patchy alveolar opacities which tend to be distributed peripherally and bilaterally. Opacities may appear like typical infective consolidation or have more of a ground glass appearance and may spontaneously migrate during the disease course, i30 27 September 2019 POSTER PRESENTATIONS
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